Janux Therapeutics, Inc. (JANX)
$17.13-0.29%Close
BUYRECOVERY · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.0B
- Beta
- 2.39
- P/E (TTM)
- -10.38
- Short % float
- 9.96%
- Days to cover
- 5.9
- SI change
- -3.5%
- 1W
- -4.41%
- 1M
- +4.20%
- vs SPY 1W
- -4.27%
- vs SPY 1M
- +1.69%
Industry peers
FMP comparable companies · ranked by market cap
- LEGNSELLLegend Biotech Corporation$3.4BRECOVERYQ 2$18.62+6.49%
- CLDXSELLCelldex Therapeutics, Inc.$2.0BCRISISQ 5$29.89-1.45%
- IMNMSELLImmunome, Inc.$1.9BCRISISQ 17$19.55-2.16%
- IMTXSELLImmatics N.V.$996MCRISISQ 5$7.43+2.49%
- CGEMSELLCullinan Therapeutics, Inc.$954MCRISISQ 1$15.53-3.26%
- CTMXSELLCytomX Therapeutics, Inc.$559MCRISISQ 6$2.57-4.29%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on JANX?
- LOPJLB’s latest quantitative signal on Janux Therapeutics, Inc. (JANX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is JANX in?
- Janux Therapeutics, Inc. (JANX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Janux Therapeutics, Inc. (JANX) do?
- Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, wh…